Fluzone HD

BIOLOGICAL4 trials

Sponsors

University of Rochester, Novavax, ModernaTX, Inc., GlaxoSmithKline

Conditions

InfluenzaInfluenza, HumanRespiratory Syncytial Virus

Phase 2

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

TerminatedNCT03658629

NovavaxInfluenza, Human

Start: 2018-09-24End: 2019-04-26Updated: 2022-11-04

A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

CompletedNCT06431607

GlaxoSmithKlineInfluenza, Human

Start: 2024-05-23End: 2025-06-04Updated: 2026-03-10

Phase 3

A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

CompletedNCT06060457

ModernaTX, Inc.Respiratory Syncytial Virus

Start: 2023-09-25End: 2024-06-07Updated: 2025-07-30

Phase 4

Comparison of Three Licensed Influenza Vaccines

CompletedNCT03068949

University of RochesterInfluenza

Start: 2015-10-28End: 2021-06-30Updated: 2021-11-30

Related Papers

Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M–Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine

Clinical Infectious Diseases2020-10-2940 citations

Comparison of Human H3N2 Antibody Responses Elicited by Egg-Based, Cell-Based, and Recombinant Protein–Based Influenza Vaccines During the 2017–2018 Season

Clinical Infectious Diseases2019-10-0447 citations